DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergen… Read more
DMK Pharmaceuticals Corporation (DMKPQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.706x
Based on the latest financial reports, DMK Pharmaceuticals Corporation (DMKPQ) has a cash flow conversion efficiency ratio of 0.706x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.74 Million) by net assets ($-5.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DMK Pharmaceuticals Corporation - Cash Flow Conversion Efficiency Trend (2016–2022)
This chart illustrates how DMK Pharmaceuticals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DMK Pharmaceuticals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DMK Pharmaceuticals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Space Kingdom Digital Capital Corp.
V:YSK-P
|
N/A |
|
Rua Life Sciences PLC
LSE:RUA
|
-0.023x |
|
Pacific Horizon Investment Trust
LSE:PHI
|
0.001x |
|
European Green Transition PLC
LSE:EGT
|
-0.143x |
|
Ces Synergies Inc
PINK:CESX
|
-2.707x |
|
Caerus Mineral Resources PLC
LSE:CMRS
|
-1.391x |
|
UCM RESITA S.A.
RO:UCM
|
0.000x |
|
PLM
WAR:PLM
|
N/A |
Annual Cash Flow Conversion Efficiency for DMK Pharmaceuticals Corporation (2016–2022)
The table below shows the annual cash flow conversion efficiency of DMK Pharmaceuticals Corporation from 2016 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-09-30 | $-650.76K | $-25.90 Million | 39.800x | +2826.29% |
| 2021-09-30 | $25.88 Million | $-37.79 Million | -1.460x | +75.57% |
| 2020-09-30 | $3.50 Million | $-20.90 Million | -5.976x | -891.75% |
| 2019-09-30 | $33.00 Million | $-19.89 Million | -0.603x | +13.85% |
| 2018-09-30 | $46.69 Million | $-32.66 Million | -0.699x | -82.79% |
| 2017-09-30 | $39.55 Million | $-15.13 Million | -0.383x | +54.29% |
| 2016-09-30 | $25.28 Million | $-21.16 Million | -0.837x | -- |